Fig. 4

MiR-371b-5p targets Smad2/LEF1 in T-LBL cells. A The predicted target sequence of miR-371b-5p in the 3’UTR of Smad2 (Smad2-3’UTR) and LEF1 (LEF1-3’UTR) and mutant containing three altered nucleotides in the seed sequence of miR-371b-5p (miR-371b-5p-mut). B Smad2/LEF1 mRNA levels in T-LBL cells after transfection with miR-371b-5p mimics and anti-miR-1258. C Luciferase assays of pGL3-Smad2-3’UTR and pGL3-LEF1-3’UTR in the presence of miR-371b-5p mimics, miR-371b-5p -mutant, and anti-miR-371b-5p. D The protein levels of Smad2 and LEF1 after transfection of T-LBL cells with miR-1258 mimics and anti-miR-1258. E MTT assays using T-LBL cells transfected by miR-371b-5p, miR-371b-5p + LEF1, miR-371b-5p + Smad2 treated with Dox (100ng/ml). F Flow cytometric analysis of T-LBL cells transfected with miR-371b-5p, miR-371b-5p + LEF1, miR-371b-5p + Smad2 treated with Dox (100ng/ml). G Smad2/LEF1 mRNA levels after transfection with LINC00183, LINC00183 + anti-miR-371b-5p, shLINC00183 and shLINC00183 + miR-371b-5p. H The protein levels of Smad2 and LEF1 after transfection of T-LBL cells with LINC00183, LINC00183 + anti-miR-371b-5p, shLINC00183 and shLINC00183 + miR-371b-5p. LINC00183, ectopic LINC00183 expression in T-LBL cells. shLINC00183, T-LBL cells were transfected by shRNA targeting LINC00183. LINC00183 + anti-miR-371b-5p, T-LBL cells were transfected with LINC00183 and anti-miR-371b-5p. shLINC00183 + miR-371b-5p, T-LBL cells were transfected with shLINC00183 and miR-371b-5p. Dox, doxorubicin. *, P < 0.05